Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo (original) (raw)

Abstract

Perlecan, a ubiquitous heparan sulfate proteoglycan, possesses angiogenic and growth-promoting attributes primarily by acting as a coreceptor for basic fibroblast growth factor (FGF-2). In this report we blocked perlecan expression by using either constitutive CMV-driven or doxycycline- inducible antisense constructs. Growth of colon carcinoma cells was markedly attenuated upon obliteration of perlecan gene expression and these effects correlated with reduced responsiveness to and affinity for mitogenic keratinocyte growth factor (FGF-7). Exogenous perlecan effectively reconstituted the activity of FGF-7 in the perlecan-deficient cells. Moreover, soluble FGF-7 specifically bound immobilized perlecan in a heparan sulfate-independent manner. In both tumor xenografts induced by human colon carcinoma cells and tumor allografts induced by highly invasive mouse melanoma cells, perlecan suppression caused substantial inhibition of tumor growth and neovascularization. Thus, perlecan is a potent inducer of tumor growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve cancer treatment.

Full Text

The Full Text of this article is available as a PDF (8.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson S. A., Bottaro D. P., Miki T., Ron D., Finch P. W., Fleming T. P., Ahn J., Taylor W. G., Rubin J. S. Keratinocyte growth factor. A fibroblast growth factor family member with unusual target cell specificity. Ann N Y Acad Sci. 1991;638:62–77. doi: 10.1111/j.1749-6632.1991.tb49018.x. [DOI] [PubMed] [Google Scholar]
  2. Adatia R., Albini A., Carlone S., Giunciuglio D., Benelli R., Santi L., Noonan D. M. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol. 1997 Dec;8(12):1257–1261. doi: 10.1023/a:1008243115385. [DOI] [PubMed] [Google Scholar]
  3. Aviezer D., Hecht D., Safran M., Eisinger M., David G., Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell. 1994 Dec 16;79(6):1005–1013. doi: 10.1016/0092-8674(94)90031-0. [DOI] [PubMed] [Google Scholar]
  4. Aviezer D., Iozzo R. V., Noonan D. M., Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol. 1997 Apr;17(4):1938–1946. doi: 10.1128/mcb.17.4.1938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–165. doi: 10.1016/s0065-230x(08)60305-x. [DOI] [PubMed] [Google Scholar]
  6. Becker D., Meier C. B., Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J. 1989 Dec 1;8(12):3685–3691. doi: 10.1002/j.1460-2075.1989.tb08543.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Benitz W. E., Kelley R. T., Anderson C. M., Lorant D. E., Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 1990 Jan;2(1):13–24. doi: 10.1165/ajrcmb/2.1.13. [DOI] [PubMed] [Google Scholar]
  8. Cohen I. R., Murdoch A. D., Naso M. F., Marchetti D., Berd D., Iozzo R. V. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res. 1994 Nov 15;54(22):5771–5774. [PubMed] [Google Scholar]
  9. Fannon M., Nugent M. A. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem. 1996 Jul 26;271(30):17949–17956. doi: 10.1074/jbc.271.30.17949. [DOI] [PubMed] [Google Scholar]
  10. Folkman J., D'Amore P. A. Blood vessel formation: what is its molecular basis? Cell. 1996 Dec 27;87(7):1153–1155. doi: 10.1016/s0092-8674(00)81810-3. [DOI] [PubMed] [Google Scholar]
  11. Forsten K. E., Courant N. A., Nugent M. A. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol. 1997 Aug;172(2):209–220. doi: 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  12. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996 Aug 9;86(3):353–364. doi: 10.1016/s0092-8674(00)80108-7. [DOI] [PubMed] [Google Scholar]
  13. Handler M., Yurchenco P. D., Iozzo R. V. Developmental expression of perlecan during murine embryogenesis. Dev Dyn. 1997 Oct;210(2):130–145. doi: 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  14. Hassell J. R., Leyshon W. C., Ledbetter S. R., Tyree B., Suzuki S., Kato M., Kimata K., Kleinman H. K. Isolation of two forms of basement membrane proteoglycans. J Biol Chem. 1985 Jul 5;260(13):8098–8105. [PubMed] [Google Scholar]
  15. Hohenester E., Sasaki T., Olsen B. R., Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J. 1998 Mar 16;17(6):1656–1664. doi: 10.1093/emboj/17.6.1656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Holmgren L., O'Reilly M. S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995 Feb;1(2):149–153. doi: 10.1038/nm0295-149. [DOI] [PubMed] [Google Scholar]
  17. Iozzo R. V., Cohen I. R., Grässel S., Murdoch A. D. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J. 1994 Sep 15;302(Pt 3):625–639. doi: 10.1042/bj3020625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Iozzo R. V. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609–652. doi: 10.1146/annurev.biochem.67.1.609. [DOI] [PubMed] [Google Scholar]
  19. Iozzo R. V., Murdoch A. D. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J. 1996 Apr;10(5):598–614. [PubMed] [Google Scholar]
  20. Iozzo R. V., Pillarisetti J., Sharma B., Murdoch A. D., Danielson K. G., Uitto J., Mauviel A. Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element. J Biol Chem. 1997 Feb 21;272(8):5219–5228. doi: 10.1074/jbc.272.8.5219. [DOI] [PubMed] [Google Scholar]
  21. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lübbert H., Bujard H. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933–10938. doi: 10.1073/pnas.93.20.10933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mathiak M., Yenisey C., Grant D. S., Sharma B., Iozzo R. V. A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res. 1997 Jun 1;57(11):2130–2136. [PubMed] [Google Scholar]
  23. Murdoch A. D., Dodge G. R., Cohen I., Tuan R. S., Iozzo R. V. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem. 1992 Apr 25;267(12):8544–8557. [PubMed] [Google Scholar]
  24. Murdoch A. D., Liu B., Schwarting R., Tuan R. S., Iozzo R. V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem. 1994 Feb;42(2):239–249. doi: 10.1177/42.2.7507142. [DOI] [PubMed] [Google Scholar]
  25. Noonan D. M., Fulle A., Valente P., Cai S., Horigan E., Sasaki M., Yamada Y., Hassell J. R. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem. 1991 Dec 5;266(34):22939–22947. [PubMed] [Google Scholar]
  26. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277–285. doi: 10.1016/s0092-8674(00)81848-6. [DOI] [PubMed] [Google Scholar]
  27. O'Reilly M. S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996 Jun;2(6):689–692. doi: 10.1038/nm0696-689. [DOI] [PubMed] [Google Scholar]
  28. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315–328. doi: 10.1016/0092-8674(94)90200-3. [DOI] [PubMed] [Google Scholar]
  29. Ornitz D. M., Yayon A., Flanagan J. G., Svahn C. M., Levi E., Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol. 1992 Jan;12(1):240–247. doi: 10.1128/mcb.12.1.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Parangi S., O'Reilly M., Christofori G., Holmgren L., Grosfeld J., Folkman J., Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2002–2007. doi: 10.1073/pnas.93.5.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Cell Biol. 1997 May;7(5):182–186. doi: 10.1016/S0962-8924(97)01037-4. [DOI] [PubMed] [Google Scholar]
  32. Santra M., Skorski T., Calabretta B., Lattime E. C., Iozzo R. V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7016–7020. doi: 10.1073/pnas.92.15.7016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sharma B., Iozzo R. V. Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem. 1998 Feb 20;273(8):4642–4646. doi: 10.1074/jbc.273.8.4642. [DOI] [PubMed] [Google Scholar]
  34. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997 Nov;3(11):1222–1227. doi: 10.1038/nm1197-1222. [DOI] [PubMed] [Google Scholar]
  35. Talmadge J. E., Fidler I. J. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J Natl Cancer Inst. 1982 Oct;69(4):975–980. [PubMed] [Google Scholar]
  36. Timar J., Ladanyi A., Lapis K., Moczar M. Differential expression of proteoglycans on the surface of human melanoma cells characterized by altered experimental metastatic potential. Am J Pathol. 1992 Aug;141(2):467–474. [PMC free article] [PubMed] [Google Scholar]
  37. Vigny M., Ollier-Hartmann M. P., Lavigne M., Fayein N., Jeanny J. C., Laurent M., Courtois Y. Specific binding of basic fibroblast growth factor to basement membrane-like structures and to purified heparan sulfate proteoglycan of the EHS tumor. J Cell Physiol. 1988 Nov;137(2):321–328. doi: 10.1002/jcp.1041370216. [DOI] [PubMed] [Google Scholar]
  38. Wang Y., Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997 Aug;3(8):887–893. doi: 10.1038/nm0897-887. [DOI] [PubMed] [Google Scholar]
  39. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan 3;324(1):1–8. doi: 10.1056/NEJM199101033240101. [DOI] [PubMed] [Google Scholar]
  40. Whitelock J. M., Murdoch A. D., Iozzo R. V., Underwood P. A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996 Apr 26;271(17):10079–10086. doi: 10.1074/jbc.271.17.10079. [DOI] [PubMed] [Google Scholar]
  41. Yayon A., Klagsbrun M., Esko J. D., Leder P., Ornitz D. M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991 Feb 22;64(4):841–848. doi: 10.1016/0092-8674(91)90512-w. [DOI] [PubMed] [Google Scholar]